TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18089335
Drug: Caspofungin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin (50 to 100 mg/day)
Study: 18090358
Drug: Estradiol level
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol level of 100 pg/mL
Study: 18090508
Drug: Escitalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (20 mg/day for 3 weeks after a 1-week titration at 10 mg/day, then increased to a maximum of 50 mg/day for 12 weeks if needed)
Study: 18090508
Drug: Escitalopram (high-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (high-dose, mean dose 33.8 mg/day at endpoint)
Study: 18096059
Drug: Vinorelbine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine (20 mg/m2) and topotecan (escalating doses of 2, 2.5, 3, 3.5, and 4 mg/m2) administered on days 1 and 8 every 21 days
Study: 18163506
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulins (IVIGs) administered at 0.5 gm/kg/day for 4 days, as additional therapy administered monthly for 6 months.
Study: 18166563
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance (50-105 mg/day)
Study: 18174826
Drug: Stimulant medication
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant medication (implied as a comparison)
Study: 18178411
Drug: Low hemoglobin
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low hemoglobin (<12.1 g/dl)
Study: 18178412
Drug: BNP >or=840
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP >or=840 pg/ml and Tn increased
Study: 18178412
Drug: BNP <840
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP <840 pg/ml and Tn not increased
Study: 18182574
Drug: Cytarabine (0.5-1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytarabine (0.5-1.5 mg/kg)
Study: 18182574
Drug: ML-DS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML-DS with history of TL
Study: 18182574
Drug: ML-DS without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ML-DS without documented TL
Study: 18184959
Drug: Sirolimus therapy
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus therapy for 12 months
Study: 18184959
Drug: Sirolimus therapy
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus therapy for 12 months (in patients with lymphangioleiomyomatosis)
Study: 18184959
Drug: 1 year
Normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 year after sirolimus therapy was discontinued
Study: 18190252
Drug: WNV DNA
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: WNV DNA vaccine (3 doses)
Study: 18191528
Drug: Preoperative chemoradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiation therapy (CRT) followed by resection
Study: 18206507
Drug: Rituximab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1000 mg, 2 intravenous applications, 2 weeks apart)
Study: 18206856
Drug: Triiodothyronine (T3)
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triiodothyronine (T3) augmentation treatment for 4 weeks
Study: 18206856
Drug: Normal control
Normalized name: Precision, Normal Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal control subjects (no treatment)
Study: 18212631
Drug: Sirolimus (SIR)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus (SIR) monotherapy
Study: 18212631
Drug: Sirolimus plus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus plus Tacrolimus (SIR-TAC) combination therapy
Study: 18221542
Drug: DC/Apo-Nec vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC/Apo-Nec vaccine (dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells)
Study: 18221542
Drug: DC/Apo-Nec vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC/Apo-Nec vaccine
Study: 18222230
Drug: Induction chemoradiotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemoradiotherapy with cisplatin and etoposide, concurrent radiation
Study: 18235052
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus vitamin D3 supplementation (1,000 mg elemental calcium plus 400 IU of vitamin D3 daily)
Study: 18237873
Drug: Peginterferon with
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon with ribavirin therapy
Study: 18249033
Drug: Early decrease
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early decrease in CA 19-9 concentration of at least 50% after two cycles of chemotherapy
Study: 18251622
Drug: Duloxetine up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine up to 120 mg/day
Study: 18253503
Drug: ICC-1132 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICC-1132 vaccine (alhydrogel-adjuvanted)
Study: 18256395
Drug: Copper-replacement therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT, THYROID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper-replacement therapy
Study: 18256395
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control group (late-diagnosis and late-treatment patients)
Study: 18284320
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 40,000 units subcutaneously once weekly until Hb > or =13 g/dl, then every 2 weeks or longer during maintenance phase.
Study: 18284320
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa administered every other week or longer during maintenance phase.
Study: 18289372
Drug: MF59-adjuvanted subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted subunit influenza vaccine (Sub/MF59; FLUAD, Novartis Vaccines)
Study: 18289372
Drug: Non-adjuvanted subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted subunit influenza vaccine (Subunit; Agrippal, Novartis Vaccines)
Study: 18289410
Drug: Procoagulant treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procoagulant treatments for oral anticoagulant treatment-intracerebral haemorrhage
Study: 18289410
Drug: Standardized treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized treatments aimed at normalization of iatrogenic coagulation impairment
Study: 18292985
Drug: GLP-1 (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 (1.0 pmol kg(-1) min(-1)) during glucose infusion
Study: 18292985
Drug: Saline during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline during glucose infusion
Study: 18296419
Drug: Oral vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vorinostat 300 mg b.i.d. 14 days/3 weeks
Study: 18296419
Drug: Oral vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vorinostat 300 mg b.i.d. 3 days/week
Study: 21300924
Drug: Oral vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vorinostat
Study: 18297527
Drug: Oral vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vorinostat 250 mg twice daily for 5 days/week/4-week cycle
Study: 18297527
Drug: Oral vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vorinostat 200 mg twice daily for 14 days/3-week cycle
Study: 18297527
Drug: Oral vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vorinostat (various doses)
Study: 18298856
Drug: Combined chelation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chelation therapy with subcutaneous deferoxamine and oral deferiprone
Study: 18300255
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m(2) every 3 weeks and gefitinib 250 mg orally, daily
Study: 18301743
Drug: Adjuvanted vaccine
Normalized name: PIKA-adjuvanted vaccine composition
DrugBank: PIKA rabies vaccine (DB17963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted vaccine (3.8 microg haemagglutinin)
Study: 18301743
Drug: Non-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted vaccine (3.8 microg haemagglutinin)
Study: 18302747
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg, one tablet daily for 4 months
Study: 18302747
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg, one tablet daily for > 4 months
Study: 18310179
Drug: Vaccine study
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine study (high risk)
Study: 18312048
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) methylphenidate
Study: 18312048
Drug: Osmotic release
Normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osmotic release oral system (OROS) methylphenidate
Study: 18315876
Drug: Dalteparin 5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin 5,000 IU once daily for a median duration of 7 days (interquartile range, 4 to 12 days)
Study: 18315876
Drug: Dalteparin 5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin 5,000 IU once daily
Study: 18332269
Drug: Simvastatin treatment
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin treatment (40 mg/d for 6 weeks)
Study: 18332796
Drug: Elevated estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elevated estradiol levels in nonsurvivors (16 pg/mL vs. 35 pg/mL, p < 0.001)
Study: 18334033
Drug: DAB/IL2 (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAB/IL2 (12 microg/kg; four daily doses; 21 day cycles)
Study: 18334676
Drug: Lenalidomide 10
Normalized name: lenalidomide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 10 mg daily with dose escalation up to 25 mg daily
Study: 28651604
Drug: Lenalidomide treatment
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide treatment
Study: 18337339
Drug: Tetravalent live-attenuated
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent live-attenuated dengue vaccine administered on Days 0 and 180
Study: 18337339
Drug: Tetravalent live-attenuated
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent live-attenuated dengue vaccine
Study: 18346516
Drug: Agalsidase beta
Normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Agalsidase beta (1 mg/kg) infused intravenously every 2 weeks for 48 weeks
Study: 18348596
Drug: Cranial electrotherapy
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial electrotherapy stimulation (CES) administered for 6 weeks using the Alpha-Stim Stress Control System at 0.5-Hz frequency and 300-muA intensity.
Study: 18349311
Drug: (90)Y microspheres,
Approvals — FDA: no, EMA: no, PMDA: no
Description: (90)Y microspheres, median activity 1.83 GBq, dose 112.8 Gy, mean number of treatments 1.6
Study: 18356759
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (14 sessions of weekly or intensive family-based)
Study: 18363467
Drug: Serum estradiol
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum estradiol cut-point of 50 pg/mL
Study: 18378607
Drug: rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 40 mg/d for 24 months
Study: 18379729
Drug: Bevacizumab 10
Normalized name: bevacizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 10 mg/kg, gemcitabine 1,000 mg/m2 at FDR infusion, cisplatin 20 mg/m2 on days 1 and 15 of a 28-day cycle
Study: 18379729
Drug: Bevacizumab 10
Normalized name: bevacizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 10 mg/kg, gemcitabine 1,000 mg/m2 at FDR infusion, cisplatin 20 mg/m2
Study: 18387850
Drug: CERE-120 (adeno-associated
Approvals — FDA: no, EMA: no, PMDA: no
Description: CERE-120 (adeno-associated virus serotype 2-neurturin) at a dose of 1.3x10(11) vg/patient
Study: 18387850
Drug: CERE-120 (adeno-associated
Approvals — FDA: no, EMA: no, PMDA: no
Description: CERE-120 (adeno-associated virus serotype 2-neurturin) at a dose of 5.4x10(11) vg/patient
Study: 18394819
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) to a dose of 6,000 cGy (Stage IA) or 6,600 cGy (Stage IB), given in three equal fractions.
Study: 18398457
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atorvastatin daily with IFN-beta comedication
Study: 18398457
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atorvastatin daily without IFN-beta comedication
Study: 18407271
Drug: Intravenous proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous proton pump inhibitors (PPI)
Study: 18416598
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) treatment at a dosage of 1 g/m(2)
Study: 18419879
Drug: Apremilast 20
Normalized name: apremilast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 20 mg orally for 29 days
Study: 18423103
Drug: Solifenacin 5/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5/10 mg/day
Study: 18426988
Drug: AMD3100 (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMD3100 (240 mug/kg by subcutaneous injection)
Study: 18436082
Drug: Calcitriol, 0.5
Normalized name: Calcitriol, 0.5 mcg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol, 0.5 microg, twice weekly for 12 weeks
Study: 18436120
Drug: Evidence-based medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medications
Study: 18436554
Drug: Tigecycline therapy
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tigecycline therapy (in combination with other antibiotics in 28 patients)
Study: 24633206
Drug: Tigecycline therapy
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tigecycline therapy
Study: 18437127
Drug: Losartan or
Normalized name: losartan Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan or Atenolol-based treatments
Study: 18441371
Drug: Subretinal injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subretinal injections of recombinant adeno-associated virus vector 2/2 expressing RPE65 cDNA
Study: 18443260
Drug: Precipitating factors
Normalized name: Precipitated Sulfur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precipitating factors identified at admission (e.g., pneumonia, ischemia, worsening renal function)
Study: 18443260
Drug: Precipitating factors
Normalized name: Precipitated Sulfur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precipitating factors identified at admission (e.g., ischemia, worsening renal function)
Study: 18447935
Drug: Good adherence
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Good adherence to antipsychotic medication (defined as less than one month without medication)
Study: 18447935
Drug: Non-adherence to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adherence to antipsychotic medication
Study: 18447935
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of depot-antipsychotics
Study: 18452610
Drug: Tremelimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab (10 mg/kg monthly)
Study: 18463354
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m(2) intravenous infusion weekly for 4 weeks)
Study: 27561198
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon plus ribavirin therapy
Study: 18471323
Drug: Isoflavone therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone therapy (soy milk containing 47 mg of isoflavonoid per 8 oz serving three times per day for 12 months)
Study: 18471323
Drug: Isoflavone therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone therapy
Study: 18474099
Drug: Liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal doxorubicin and paclitaxel in combination with whole breast hyperthermia
Study: 18477658
Drug: U-Na measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: U-Na measurement in patients not on diuretics
Study: 18477658
Drug: FE-UA measurement
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: FE-UA measurement in patients on diuretics
Study: 18477658
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of U-Na and FE-UA
Study: 18485781
Drug: Premarin estrogen
Normalized name: estrogens, conjugated (USP) Injection [Premarin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin estrogen replacement therapy (ERT)
Study: 18504251
Drug: Bortezomib 1
Normalized name: bortezomib 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1 mg/m(2) on days 1, 4, 8, and 11 plus gemcitabine 800 mg/m(2) on days 1 and 8
Study: 18504251
Drug: Bortezomib and
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib and gemcitabine combination
Study: 18507871
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of influenza vaccine (129 patients)
Study: 18507871
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of influenza vaccine (100 patients)
Study: 18509084
Drug: Autologous T
Normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous T cells genetically modified by electroporation with a vector plasmid encoding a CD20-specific chimeric T-cell receptor and neomycin resistance gene
Study: 18509084
Drug: Low-dose subcutaneous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subcutaneous interleukin-2 (IL-2) injections
Study: 18514203
Drug: Baseline plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline plasma IL-18 levels (274.1 pg/mL) in women who developed CVD
Study: 18514203
Drug: IL-18 levels
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-18 levels at or above the 90th percentile (442 pg/mL)
Study: 18514203
Drug: Baseline plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline plasma IL-18 levels (233.8 pg/mL) in healthy controls
Study: 18522979
Drug: Graded estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graded estrogen infusion
Study: 18523152
Drug: Anti-CTLA4 antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-CTLA4 antibody
Study: 18535255
Drug: Lung volume
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung volume reduction surgery (surgical treatment)
Study: 18535255
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (medical treatment)
Study: 18545693
Drug: L-arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine infusion (3 g, 6 g, 12 g)
Study: 18545693
Drug: L-arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine infusion (12 g)
Study: 18554762
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF), 600 mg/m(2)/dose, twice daily for 24 months.
Study: 18554762
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) treatment for 18.6 +/- 8.0 months, with a final dosage of 381 +/- 241 mg/m(2) twice daily.
Study: 18559166
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER (10.5 mg daily for an average of 167 days)
Study: 18559695
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg/d for 6 weeks
Study: 18559696
Drug: Aliskiren (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (600 mg)
Study: 18582371
Drug: The Treatment
Normalized name: Thein
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Treatment Perspective (16 week supervised training intervention including motivational counselling)
Study: 18584946
Drug: Antimuscarinics (tolterodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimuscarinics (tolterodine ER 4 mg once daily)
Study: 18584946
Drug: Antimuscarinics (tolterodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimuscarinics (tolterodine ER 4 mg once daily) + local oestrogens (oestriol cream application once daily)
Study: 18593770
Drug: Octreotide-long-acting release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide-long-acting release (LAR) therapy at a dose of 20 mg every 28 days for 3 months